Please wait a minute...
 Home  Journals Subscription Open Access About Us
Just Accepted  |  Online First  |  Current Issue  |  Archive  |  Special Issues  |  Featured Articles  |  Most Downloaded
Journal of Translational Neuroscience    2016, Vol. 1 Issue (1) : 37-42
Why sex differences in schizophrenia?
Rena Li1,2,3*, Xin Ma1, Gang Wang1, Jian Yang1, Chuanyue Wang1,2
1. Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital Capital Medical University, Beijing 100088, China;
2. Center of Schizophrenia, Beijing Institute for Brain Disorders, Beijing 100069, China;
3. Center for Hormone Advanced Science and Education, Roskamp Institute, Sarasota, FL 34243, USA
Download: PDF(281 KB)  
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract Clinical observation shows that men and women are different in prevalence, symptoms, and responses to treatment of several psychiatric disorders, including schizophrenia. While the etiology of gender differences in schizophrenia is only partially understood, recent genetic studies suggest significant sex-specific pathways in the schizophrenia between men and women. More research is needed to understand the causal roles of sex differences in schizophrenia in order to ultimately develop sex-specific treatment of this serious mental illness. In the present review, we will outline the current evidence on the sex-related factors interaction with disease onset, symptoms and treatment of schizophrenia, and discuss the potential molecular mechanisms that may mediate their cooperative actions in schizophrenia pathogenesis.
Keywords schizophrenia      gender-related factor      sex-specific treatment     
Corresponding Author(s): *Rena Li,   
Issue Date: 14 October 2016
 Cite this article:   
Rena Li,Xin Ma,Gang Wang, et al. Why sex differences in schizophrenia?[J]. Journal of Translational Neuroscience, 2016, 1(1): 37-42.
E-mail this article
E-mail Alert
Articles by authors
Rena Li
Xin Ma
Gang Wang
Jian Yang
Chuanyue Wang
[1] Nawka A, Kalisova L, Raboch J, et al. TW. Gender differences in coerced patients with schizophrenia. BMC Psychiatry, 2013, 13: 257.
[2] Jones PB. Adult mental health disorders and their age at onset. Br J Psychiatry, 2013, 54(Suppl): S5-S10.
[3] Kirkbride JB, Errazuriz A, Croudace TJ, et al. Incidence of schizophrenia and other psychoses in England, 1950-2009: a systematic review and meta-analyses. PLoS ONE, 2012, 7(3): e31660.
[4] Nowrouzi B, Kamhi R, Hu J, et al. Age at onset mixture analysis and systematic comparison in schizophrenia spectrum disorders: Is the onset heterogeneity dependent on heterogeneous diagnosis? Schizophr Res, 2015, 164(1-3): 83-91.
[5] Angermeyer MC, Kühn L. Gender differences in age at onset of schizophrenia. An overview.Eur Arch Psychiatry Neurol Sci, 1988, 237(6): 351-364.
[6] Takei N, O'Callaghan E, Sham P, et al. Seasonality of admissions in the psychoses: effect of diagnosis, sex, and age at onset. Br J Psyehiat, 1992, 161: 506-511.
[7] Howard R, Jeste D. Late onset schizophrenia.//Weinberger DR, Harrison PJ. Schizophrenia. Chichester, West Sussex: WileyBlackwell, 2011: 47-61.
[8] Ali Bani Fatemi CZ, De Luca V. Early onset schizophrenia: gender analysis of genome-wide potential methylation. Clin Chim Acta, 2015, 449: 63-67.
[9] Frydecka D, Misiak B, Pawlak-Adamska E, et al. Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia. Neuropsychiatr Dis Treat, 2015, 11: 575-584.
[10] Rietschel L, Lambert M, Karow A, et al. Clinical high risk for psychosis: gender differences in symptoms and social functioning. Early Interv Psychiatry, 2015, Mar 24.doi: 10.1111/eip.12240. [Epub ahead of print]
[11] Lindamer LA, Lohr JB, Harris MJ, et al. Gender-related clinical differences in older patients with schizophrenia. J Clin Psychiatry, 1999, 60(1): 61-67.
[12] Han M, Huang XF, Chen Da C, et al. Gender differences in cognitive function of patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry, 2012, 39(2): 358-363.
[13] Fine C. Neuroscience. His brain, her brain? Science, 2014, 346(6212): 915-916
[14] Ingalhalikar M, Smith A, Parker D, et al. Sex differences in the structural connectome of the human brain. Proc Natl Acad Sci USA, 2014, 111(2): 823-828.
[15] Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol, 2014, 14(1): 97-102.
[16] de Castro-Catala M, Barrantes-Vidal N, Sheinbaum T, et al. COMT-by-sex interaction effect on psychosis proneness. Biomed Res Int, 2015, 829237.
[17] Bristow GC, Bostrom JA, Haroutunian V, et al. Sex differences in GABAergic gene expression occur in the anterior cingulate cortex in schizophrenia. Schizophr Res, 2015, 167(1-3): 57-63.
[18] Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia.Int Rev Psychiatry, 2010, 22(5): 417-428.
[19] Riecher-R ssler A, H fner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl, 2000,(407): 58-62.
[20] Grigoriadis S, Seeman MV. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry, 2002, 47(5): 437-442.
[21] Desai PR, Lawson KA, Barner JC, et al. Identifying patient characteristics associated with high schizophrenia-related direct medical costs in community-dwelling patients. J Manag Care Pharm, 2013, 19(6): 468-477.
[22] Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry, 2010, 22(5): 472-484.
[23] Kulkarni J, de Castella A, Headey B, et al. Estrogens and men with schizophrenia: is there a case for adjunctive therapy? Schizophr Res, 2011, 125(2-3): 278-283.
[24] Bushe C, Yeomans D, Floyd T, et al. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. J Psychopharmacol, 2008, 22(2 Suppl): 56-62.
[25] Seeman MV. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry, 2004, 161(8): 1324-1333.
[26] Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: Epidemiology and therapeutic implications. CNS Drugs, 2001, 15(7): 537-551.
[27] Seeman MV. Secondary effects of antipsychotics: Women at greater risk than men. Schizophr Bull, 2009, 35(5): 937-948.
[28] Morken G, Widen J, Grawe R. Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia. BMC Psychiatry, 2008, 8 (1): 32.
[29] Brabban A, Tai S, Turkington D. Predictors of outcome in brief cognitive behavior therapy for schizophrenia. Schizophr Bull, 2009, 35(5): 859-864.
[30] Riecher-Rossler A, Pfluger M, Borgwardt S. Schizophrenia in women. //Kohen D. Oxford textbook of women and mental health. Oxford: Oxford University Press, 2010: 102-111.
[31] Grigoriadis S, Seeman MV. The role of estrogen in schizophrenia: implications for schizophrenia practice guidelines for women. Can J Psychiatry, 2002, 47: 437-442.
[32] Kaneda Y, Ohmori T. Relation between estradiol and negative symptoms in men with schizophrenia. J Neuropsychiatry Clin Neurosci, 2005, 17(2): 239-242.
[33] Sumner BE, Fink G. Effects of acute estradiol on 5-hydroxytryptamine and dopamine receptor subtype mRNA expression in female rat brain. Mol Cell Neurosci, 1993, 4(1):83-92.
[34] Fink G, Sumner BE, McQueen JK, et al. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol, 1998, 25(10):764-775.
[35] Sánchez MG, Bourque M, Morissette M, et al. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther, 2010, 16(3): e43-e71.
[36] Ritsner MS, Gibel A, Ram E, et al. Alterations in DHEA-metabolism in schizophrenia: two-month case-control study. Eur Neuropsychopharmacol, 2006, 16: 137-146.
[37] Ko YH, Jung SW, Joe SH, et al. Association between serum testosterone levels and the severity of negative symptoms in male patients with chronic schizophrenia. Psychoneuroendocrinology, 2007, 32(4): 385-391.
[38] Sisek-prem M, Kriaj A, Juki V, et al. Testosterone levels and clinical features of schizophrenia with emphasis on negative symptoms and aggression. Nord J Psychiatry, 2015, 69(2): 102-109.
[39] Sasayama D, Hattori K, Teraishi T, et al. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr Res, 2012, 139(1-3): 201-206.
[40] Cochran DM, Fallon D, Hill M, et al. The role of oxytocin in psychiatric disorders: a review of biological and therapeutic research findings. Harv Rev Psychiatry, 2014, 21(5): 219-247.
[41] Frost K, Keller W, Buchanan R, et al. Plasma oxytocin levels are associated with impaired social cognition and neurocognition in schizophrenia. Arch Clin Neuropsychol, 2014, 29(6): 577-578.
[42] Feifel D. Is oxytocin a promising treatment for schizophrenia? Expert Rev Neurother, 2011, 11(2): 157-159.
[43] Hong DS, Reiss AL. Cognitive and neurological aspects of sex chromosome aneuploidies. Lancet Neurol, 2014, 13(3): 306-318.
[44] DeLisi LE, Friedrich U, Wahlstrom J, et al. Schizophrenia and sex chromosome anomalies. Schizophr Bull, 1994, 20(3): 495-505.
[45] DeLisi LE, Devoto M, Lofthouse R, et al. Search for linkage to schizophrenia on the X and Y chromosomes. Am J Med Genet, 1994, 54(2): 113-121.
[46] Crow TJ, DeLisi LE, Lofthouse R, et al. An examination of linkage of schizophrenia and schizoaffective disorder to the pseudoautosomal region(Xp22.3). Br J Psychiatry, 1994, 164(2): 159-164.
[47] Dann J, DeLisi LE, Devoto M, et al. A linkage study of schizophrenia to markers within Xp11 near the MAOB gene. Psychiatry Res, 1997, 70(3): 131-143.
[48] Demirhan O, Ta temir D. Chromosome aberrations in a schizophrenia population. Schizophr Res, 2003, 65(1): 1-7.
[49] Crow TJ. The XY gene hypothesis of psychosis: origins and current status. Am J Med Genet B Neuropsychiatr Genet, 2013, 162(8): 800-824.
[50] Goldstein JM, Cherkerzian S, Seidman LJ, et al. Sex-specific rates of transmission of psychosis in the New England high-risk family study. Schizophr Res, 2011, 128(1-3): 150-155.
Related articles from Frontiers Journals
[1] Yanbing Xiong, Xianbin Li, Zhen Mao, Lei Zhao, Yilang Tang, Chuanyue Wang. Prepulse inhibition deficits in antipsychotic-naïve first-episode schizophrenia: a meta-analysis[J]. Journal of Translational Neuroscience, 2018, 3(2): 23-34.
[2] Zhemeng Wu, Qian Wang. Cognitive deficits in schizophrenia: from pharmacology to neurocognitive models[J]. Journal of Translational Neuroscience, 2018, 3(1): 1-11.
[3] Anthony J Hannan. Optimising validity and translational potential in rodent models of brain disorders[J]. Journal of Translational Neuroscience, 2016, 1(2): 56-62.
Full text



Copyright © 2014 Higher Education Press, All Rights Reserved. Powered by Beijing Magtech Co. Ltd
京ICP备12020869号-1 京ICP证150856号  京公网安备 11010202008535号
Service: 010-58556313 (Technology); 010-58556485 (Subscription) E-mail: